Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 15/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.46 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.46 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.46 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | DDB1 | Q16531 | 2/20 | 0.41 |
| ▸ | OTUD7B | Q6GQQ9 | 1/20 | 0.40 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11066896 | 0.91 | CRBN (0.44) | CRBNNPC1MAPK13MAPK12MAPK11 | |
| SCHEMBL259592 | 0.86 | CRBN (0.44) | CRBNNPC1MAPK13MAPK12MAPK11 | |
| SCHEMBL19586472 | 0.80 | TDP2 (0.44) | CRBN | |
| SCHEMBL261144 | 0.74 | CALCRL (0.39) | OTUD7B | |
| SCHEMBL11067414 | 0.74 | ADRA2A (0.54) | CRBNMAPT | |
| SCHEMBL24204269 | 0.73 | OTUD7B (0.54) | NPC1MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL11071163 | 0.73 | TDP2 (0.44) | CRBNDDB1 | |
| SCHEMBL19586434 | 0.72 | CRBN (0.55) | CRBN | |
| SCHEMBL3991604 | 0.72 | GRIN1 (0.43) | MAPTOTUD7B | |
| SCHEMBL22932167 | 0.71 | CRBN (0.56) | CRBNDDB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11185592-B2 | Spirocyclic degronimers for target protein degradation | C4 THERAPEUTICS, INC. (US) | 2021-11-30 | — | — | US | disclosed |
| US-20210106688-A1 | SPIROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | C4 THERAPEUTICS, INC. (US) | 2021-04-15 | — | — | US | disclosed |
| US-10660968-B2 | Spirocyclic degronimers for target protein degradation | C4 THERAPEUTICS, INC. (US) | 2020-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11185592-B2 | Spirocyclic degronimers for target protein degradation | STUB1, UBE3C, UBE3A | CRBN 115/4885NPC1 2188/4885MAPK13 1782/4885 |
| US-20210106688-A1 | SPIROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | STUB1, UBE3C, UBE3A | CRBN 115/4885NPC1 2188/4885MAPK13 1782/4885 |
| US-10660968-B2 | Spirocyclic degronimers for target protein degradation | STUB1, UBE3C, UBE3A | CRBN 115/4885NPC1 2188/4885MAPK13 1782/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.